Abstract
The treatment of metastatic colorectal cancer (mCRC) has changed dramatically from the 1980s, when only fluorouracil (5-FU) was available for treatment and the median survival was at best 12 months, to a time when mCRC is considered more of a chronic disease in which the median survival is now reported in excess of 2 years. This review traces the evolution of treatment in this setting, including studies of single-agent vs combination treatment with 5-FU/leucovorin, irinotecan, oxaliplatin, and capecitabine, comparisons of simultaneous and sequential regimens, and the role of targeted agents such as bevacizumab, cetuximab, and panitumumab.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab
-
Biomarkers, Tumor / metabolism
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Capecitabine
-
Celecoxib
-
Cetuximab
-
Clinical Trials as Topic
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / pathology*
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Erlotinib Hydrochloride
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Humans
-
Irinotecan
-
Leucovorin / administration & dosage
-
Meta-Analysis as Topic
-
Mitomycin / administration & dosage
-
Organoplatinum Compounds / administration & dosage
-
Oxaliplatin
-
Panitumumab
-
Prognosis
-
Pyrazoles / administration & dosage
-
Quinazolines / administration & dosage
-
Randomized Controlled Trials as Topic
-
Sulfonamides / administration & dosage
-
Survival Analysis
-
Treatment Outcome
-
Vitamin B Complex / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Organoplatinum Compounds
-
Pyrazoles
-
Quinazolines
-
Sulfonamides
-
Oxaliplatin
-
Deoxycytidine
-
Vitamin B Complex
-
Bevacizumab
-
Mitomycin
-
Capecitabine
-
Panitumumab
-
Irinotecan
-
Erlotinib Hydrochloride
-
Celecoxib
-
Cetuximab
-
Leucovorin
-
Fluorouracil
-
Camptothecin